Xarelto Lawsuit Challenges Xarelto Daily Dosage Effectiveness

A newly filed Xarelto lawsuit challenged the 24-hours efficacy of the dreaded blood thinner medication. One of the main selling points of the overhyped blood thinner Xarelto was its “one size fits all” dosage. Xarelto did not require dose adjustment or constant blood monitoring, as a single pill every day was deemed sufficient to prevent… Read More »

Xarelto Defense Attorney trembles as FDA and EMA review ROCKET-AF Trial

All the Xarelto injury lawyers who brought Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) before the United States District Court for the Eastern District of Louisiana for the Xarelto Multi-District Litigation now rejoice. The Xarelto defending attorney should be scared, in fact, as the largest trial that demonstrated Xarelto safety and… Read More »

Xarelto side effects – uncontrollable bleeding kills another man

Victims of the infamous blood-thinner Xarelto keep mounting up. A new  Xarelto lawsuit has been filed by a man in Georgia, Louisiana against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), the pharmaceutical companies that manufactured the dangerous Novel Oral Anticoagulant (NOAC). The plaintiff accuses the Big Pharma of the death of… Read More »

New Xarelto Lawsuit in Vermont Man dies of internal bleeding

The infamous blood thinner Xarelto probably killed another victim. The Novel Oral Anticoagulant (NOAC) drug produced by Bayer AG has been the target of several Xarelto lawsuits over the course of the last few years. Plaintiffs accuse the pharmaceutical company of fraudulent misrepresentation of the drug’s safety, negligence in providing adequate warning to patients as well… Read More »

A new Xarelto Lawsuit emerges: Medication’s once-daily dosage could be unsafe

Recently, in the Pennsylvania State Court a new Xarelto Lawsuit has been filed against the medication’s manufacturers Janssen Pharmaceuticals. More than 1,700 federal Xarelto litigations have been filed in the last few years accusing the pharmaceutical of negligence in properly warning their patients about the life-threatening dangers of the blood-thinning drug. Xarelto was, in fact,… Read More »

FDA grants approval for Pradaxa antidote. What about Xarelto?

On October 16,2015, the US Food and Drugs Administration (FDA) granted approval for Praxbind (idarucizumab) an antidote to reverse Pradaxa (dabigatran) effects. Praxbind is a humanized monoclonal antibody fragment that binds to Pradaxa, stopping the powerful Novel Oral Anticoagulant (NOAC) effects, whenever a serious adverse reaction like internal bleeding occurs. But what about Pradaxa’s close brother, the other… Read More »

Xarelto Latest News: Bellwether Trials Finally Set in 2017

Finally the dates for the Xarelto bellwether trials have been set. The Xarelto litigation keeps on growing as new lawsuits are filed every day, the latest one from a widow in Florida who claims that Xarelto medication caused her husband’s untimely death because of a fatal internal bleeding. Although the litigation is still on the pretrial stages, the dates have… Read More »

The history of the anticoagulant Xarelto

The U.S. Food and Drug Administration (FDA) approved the blood thinner Xarelto (Rivaroxaban) in 2011. However, the highly-controversial anticoagulant caused thousands of lethal bleeding events and injuried many patients who took it, in less than four years. Other Novel Oral Anticoagulants (NOACs) such as Pradaxa (dabigatran) and Eliquis (apixaban) also caused many adverse reactions, leading to… Read More »

When did Xarelto Advertisement Decided To Lie?

In what is probably one of the boldest allegations to come to light in the last few years, plaintiffs accuse Johnson (J&J) and Bayer Corp. (Bayer ) of false advertisement claims regarding Xarelto’s safety, in particular as the pharmaceutical companies deliberately avoided to adequately warn patients about the dangerous consequences of the absence of a… Read More »